| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/26/2000 | EP0994896A1 Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 04/26/2000 | EP0994887A2 Modified glycosides, compositions comprised thereof and methods of use thereof |
| 04/26/2000 | EP0994725A1 Thermodynamic adaptive phased array system for activating thermosensititve liposomes in targeted drug delivery |
| 04/26/2000 | EP0994711A1 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and rnal function |
| 04/26/2000 | EP0994709A1 Calcium blockers to treat proliferative vitreoretinopathy |
| 04/26/2000 | EP0994702A2 Medicament comprising adenosine |
| 04/26/2000 | EP0983037A4 Antifungal nail lacquer and method using same |
| 04/26/2000 | EP0925305B1 Cyclitol containing carbohydrates from human tissue which regulate lipogenic activity |
| 04/26/2000 | EP0925304B1 Cyclitol containing carbohydrates from human tissue which regulate glycogen metabolism |
| 04/26/2000 | CN1251612A Novel compound |
| 04/26/2000 | CN1251532A Tissue factor methods and compositions for coagulation and tumor treatment |
| 04/26/2000 | CN1251531A Treatment of inner ear hair cells |
| 04/26/2000 | CN1251530A Use of substaces having oxytocin activity for preparation of medicaments for wound healing |
| 04/26/2000 | CN1251526A New therapeutic combinations of mirtazapine and antipsychotic agents, for treatment of prophylaxis of psychotic disorders |
| 04/26/2000 | CN1251525A Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as medicines for treating AIDS |
| 04/26/2000 | CN1251520A Use of sodium channel blocker in manfacture of medicament for preventing optic nerve degeneration associated with glaucoma |
| 04/26/2000 | CN1251312A Stable complex of insoluble chemical compound |
| 04/26/2000 | CN1051767C Benzoxazinones as inhibitors of HIV reverse transcriptase |
| 04/25/2000 | US6054560 Mitogen activated protein kinase, FRK |
| 04/25/2000 | US6054559 Interleukin-1 receptor antagonist beta (IL-1raβ) |
| 04/25/2000 | US6054555 Process for the preparation of immobilized and activity-stabilized complexes of LHRH antagonists |
| 04/25/2000 | US6054490 Use of sesquiterpenes for inhibiting oxidative enzymes |
| 04/25/2000 | US6054485 Eye treatments using synthetic thyroid hormone compositions |
| 04/25/2000 | US6054467 Induction of apoptosis in cancer cells following treatment with inhibitors of dna repair in combination with p53. |
| 04/25/2000 | US6054463 Methods for treating dermatitis using descarboethoxyloratadine |
| 04/25/2000 | US6054455 Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia |
| 04/25/2000 | US6054445 Kappa opioid agonist activity; analgesics and anti-pruritic agents |
| 04/25/2000 | US6054432 Means for treating prostate hypertrophy and prostate cancer |
| 04/25/2000 | US6054431 Anti-gram-positive bacterial methods and materials |
| 04/25/2000 | US6054320 Includes a regent which binds to effector of arachidonic acid release in biopsy sample cells and another reagent for detectably labelling binding agent; for early, accurate diagnosis |
| 04/25/2000 | US6054292 T-cell receptor protein |
| 04/25/2000 | US6054273 Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
| 04/22/2000 | CA2285749A1 Novel proteins from actinobacillus pleuropneumoniae |
| 04/21/2000 | CA2287139A1 Method for treating congestive heart failure |
| 04/21/2000 | CA2287122A1 Treatment of bph with cgmp elevators |
| 04/20/2000 | WO2000022143A2 Protein kinase homologs |
| 04/20/2000 | WO2000022142A2 Cell signaling polypeptides and nucleic acids |
| 04/20/2000 | WO2000022129A1 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 04/20/2000 | WO2000022125A2 6-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same |
| 04/20/2000 | WO2000022121A2 Ion channels, in particular vanilloid receptor-like (vr-l) receptor |
| 04/20/2000 | WO2000022120A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 04/20/2000 | WO2000021996A2 Methods and compositions for inhibiting neoplastic cell growth |
| 04/20/2000 | WO2000021988A2 Human ankyrin family protein |
| 04/20/2000 | WO2000021987A2 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease |
| 04/20/2000 | WO2000021934A1 Compounds |
| 04/20/2000 | WO2000021926A2 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 04/20/2000 | WO2000021572A2 Hydrogels and water soluble polymeric carriers for drug delivery |
| 04/20/2000 | WO2000021565A1 Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent |
| 04/20/2000 | WO2000021564A1 Composition and method for treating allergic diseases |
| 04/20/2000 | WO2000021560A1 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY |
| 04/20/2000 | WO2000021558A1 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway |
| 04/20/2000 | WO2000021557A1 Delta 6 fatty acid desaturase |
| 04/20/2000 | WO2000021542A1 Methods for stimulating bone formation |
| 04/20/2000 | WO2000021538A1 A method of modulating ion channel functional activity |
| 04/20/2000 | WO2000021532A1 Methods for inhibiting bone resorption |
| 04/20/2000 | WO2000021530A1 Peripherally acting anti-pruritic opiates |
| 04/20/2000 | WO2000021523A1 Methods for regulating bone formation |
| 04/20/2000 | WO2000021520A2 Opioid analgesic |
| 04/20/2000 | WO2000021515A2 Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
| 04/20/2000 | WO2000021514A2 Method and composition for treating and preventing tuberculosis |
| 04/20/2000 | WO2000021512A2 Composition and method for treating allergic diseases |
| 04/20/2000 | WO2000021509A2 Methods of treatment |
| 04/20/2000 | WO2000021508A2 Novel therapeutic use of compounds with beta-3-agonist activity |
| 04/20/2000 | WO2000007616A3 Use of novel agents inducing cell death in synergy with interferons |
| 04/20/2000 | WO2000003749A3 Method for regulating hair growth |
| 04/20/2000 | WO2000003746A3 Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
| 04/20/2000 | WO2000003737A3 Water-soluble drugs and methods for their production |
| 04/20/2000 | WO2000003004A3 Presenilin 2 specific ribozyme |
| 04/20/2000 | WO2000001713A9 Diacylglycerol acyl transferase proteins |
| 04/20/2000 | WO2000000622A3 Human oxidoreductase proteins |
| 04/20/2000 | WO1999067407A3 Transgenetic non-human animal which comprises an inactive peg3 gene, and the use thereof |
| 04/20/2000 | WO1999066958A3 Use of a compound having affinity for the benzodiazepine mitochondrial receptor in cancer therapy |
| 04/20/2000 | WO1999066065A3 Proteasomal activity |
| 04/20/2000 | WO1999064050A9 Novel potassium channel drugs and their uses |
| 04/20/2000 | WO1999064000A9 Novel therapeutic agents that modulate neurokinin receptors |
| 04/20/2000 | WO1999063981A3 Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells |
| 04/20/2000 | WO1999061469A3 Prostate growth-associated membrane proteins |
| 04/20/2000 | WO1999060986A3 Apoptosis modulators that interact with the huntington's disease gene |
| 04/20/2000 | WO1999058947A9 Modulation of molecular interaction sites on rna and other biomolecules |
| 04/20/2000 | DE19847969A1 Stable liquid formulation of formoterol in solution or suspension medium, used after dilution for treatment of asthma by inhalation |
| 04/20/2000 | DE19847968A1 Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit. |
| 04/20/2000 | CA2450824A1 Methods and compositions for inhibiting neoplastic cell growth |
| 04/20/2000 | CA2347653A1 Novel cell signaling polypeptides and nucleic acids |
| 04/20/2000 | CA2347121A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 04/20/2000 | CA2347113A1 Human ankyrin family protein |
| 04/20/2000 | CA2346813A1 Method and composition for treating and preventing tuberculosis |
| 04/20/2000 | CA2346775A1 Protein kinase homologs |
| 04/20/2000 | CA2346464A1 Peripherally acting anti-pruritic opiates |
| 04/20/2000 | CA2346329A1 Hydrogels and water soluble polymeric carriers for drug delivery |
| 04/20/2000 | CA2346228A1 Composition and method for treating allergic diseases |
| 04/20/2000 | CA2346227A1 Composition and method for treating allergic diseases |
| 04/20/2000 | CA2346038A1 Methods for inhibiting bone resorption |
| 04/20/2000 | CA2346036A1 Methods for regulating bone formation |
| 04/20/2000 | CA2346031A1 Methods for stimulating bone formation |
| 04/20/2000 | CA2346008A1 G-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same |
| 04/20/2000 | CA2346006A1 Delta 6 fatty acid desaturase |
| 04/20/2000 | CA2344465A1 Methods and compositions for inhibiting neoplastic cell growth |
| 04/20/2000 | CA2342314A1 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 04/19/2000 | EP0993831A2 Compounds and compositions for delivering active agents |
| 04/19/2000 | EP0993613A2 Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumours originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma |